liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP)
Danderyd Hospital, Sweden .
Hallands Hospital, Sweden .
Danderyd Hospital, Sweden .
Danderyd Hospital, Sweden .
Show others and affiliations
2013 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 15, no 1, 135-140 p.Article in journal (Refereed) Published
Abstract [en]

Atrial fibrillation (AF) is important because it is common and is a major cause of stroke unless treated with oral anticoagulant. The prevalence of AF increases with age as does the risk of stroke. At 75 years the risk from age alone is so high that current guidelines recommend anticoagulation even in the absence of other risk factors. Atrial fibrillation is often asymptomatic and only discovered by chance or when a stroke already has occurred. less thanbrgreater than less thanbrgreater thanWe have launched a major screening study for silent AF in which 25 000 Swedes aged 75 and 76 years are randomized to either participate in a screening programme using ambulant intermittent electrocardiogram (ECG) recording to detect silent AF, or act as a control group. Patients in whom AF is detected are offered cardiological examination and anticoagulant treatment according to current guidelines. The cohort and the controls will be followed prospectively for 5 years after the inclusion of the first participant. An interim analysis will be made after 3 years. less thanbrgreater than less thanbrgreater thanOur hypothesis is that screening for AF will reduce stroke incidence in the screened population, and that this screening will prove to be cost effective. Secondary endpoints are: any thromboembolic event, intracranial bleeding, other major bleeding, first ever diagnosis of dementia, death from any cause, and a composite of these endpoints.

Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B , 2013. Vol. 15, no 1, 135-140 p.
Keyword [en]
Atrial fibrillation, Silent atrial fibrillation, Epidemiology, Stroke, Bleeding, Anticoagulation, Screening
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-87455DOI: 10.1093/europace/eus217ISI: 000312642400026OAI: oai:DiVA.org:liu-87455DiVA: diva2:589497
Note

Funding Agencies|AstraZeneca||Boehringer Ingelheim||sanofi-aventis||Swedish Heart and Lung Foundation||Vinnvard Foundation||Stockholm County Council||Scientific Council of Region Halland||Council of Health Care in Southern Sweden||

Available from: 2013-01-18 Created: 2013-01-18 Last updated: 2017-12-06

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Levin, Lars-Åke

Search in DiVA

By author/editor
Levin, Lars-Åke
By organisation
Health Technology Assessment and Health EconomicsFaculty of Health Sciences
In the same journal
Europace
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 68 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf